Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases

A novel immunoassay specific for the osteoclast-produced tartrate-resistant acid phosphatase TRAP isoform 5b was developed some years ago. By means of this assay, the usefulness of serum TRAP in monitoring the response to palliative treatment with clodronate in breast cancer patients with bone metas...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental obstetrics & gynecology 2009, Vol.36 (4), p.219-225
Main Authors: Tauchert, S, di Liberto, A, Cordes, T, Thill, M, Salehin, D, Friedrich, M
Format: Article
Language:English
Subjects:
Acid Phosphatase - blood
Biomarkers - blood
Bone Density Conservation Agents - therapeutic use
Bone Neoplasms - blood
Bone Neoplasms - secondary
Bone Resorption - blood
Breast Neoplasms - pathology
Clodronic Acid - therapeutic use
Female
Humans
Isoenzymes - blood
Palliative Care
Tartrate-Resistant Acid Phosphatase
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A novel immunoassay specific for the osteoclast-produced tartrate-resistant acid phosphatase TRAP isoform 5b was developed some years ago. By means of this assay, the usefulness of serum TRAP in monitoring the response to palliative treatment with clodronate in breast cancer patients with bone metastases was studied. Serum TRAP was examined for correlation with the activity of bone osteoclasts in these patients. Seventeen patients took part in this study taking 1600 mg clodronate daily as a tablet for five months. Eleven of these patients were evaluated. TRAP activity correlated well with the grade of bone metastases and with the number of locations in the body. During the therapy with clodronate, TRAP activity in serum decreased. We conclude that the measurement of TRAP is useful in monitoring treatment with bisphosphonate clodronate in patients with bone metastatic breast cancer.
ISSN:0390-6663